Get started
Author

Yehonatan Elon

Observed name: Y. Elon
Institution: Adama (Israel)
Observed institution: Adama (Israel)
OpenAlex ID: A5013360436
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
2022 · Michal Harel, Coren Lahav, et al. · Journal for ImmunoTherapy of Cancer · 43
PDF
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
2024 · Petros Christopoulos, Michal Harel, et al. · JCO Precision Oncology · 22
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
2024 · Jair Bar, Raya Leibowitz, et al. · Frontiers in Immunology · 15
Analytical validation of the PROphet test for treatment decision-making guidance in metastatic non-small cell lung cancer
2023 · Ben Yellin, Coren Lahav, et al. · Journal of Pharmaceutical and Biomedical Analysis · 7
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
2025 · Michal Harel, Nili Dahan, et al. · Journal for ImmunoTherapy of Cancer · 5
Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma.
2025 · Clara Steiner, Eddy Saad, et al. · Journal of Clinical Oncology · 4
PDF
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer
2024 · David R. Gandara, Janakiraman Subramanian, et al. · Clinical Lung Cancer · 4
PDF
Integration of proteomic and clinical data for the prediction of response to immune checkpoint inhibitor therapy in non-small cell lung cancer.
2021 · Yuval Shaked, Michal Harel, et al. · Journal of Clinical Oncology · 3
1707P A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
2024 · E. Saad, R.M. Saliby, et al. · Annals of Oncology · 2
Abstract 1208: Plasma proteomics-based models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy
2024 · Michal Harel, Petros Christopoulos, et al. · Cancer Research · 2
A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma
2026 · Clara Steiner, Tiegang Han, et al. · Cancers · 1
PDF
43 DSG2 and NPNT are Elevated in the Plasma of Metastatic Chromophobe RCC and are Associated with Poorer Overall Survival
2026 · Tiegang Han, Clara Steiner, et al. · The Oncologist
PDF
Abstract 2452: Proteomic aging biomarkers predict survival in immunotherapy-treated tumors
2026 · Michal Harel, Coren Lahav, et al. · Cancer Research
Abstract B024: A mitochondrial plasma proteomic signature identifies metastatic chromophobe RCC
2026 · Tiegang Han, Clara Steiner, et al. · Cancer Research
Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies
2026 · Coren Lahav, Nili Dahan, et al. · Journal of Pharmaceutical and Biomedical Analysis
A Plasma Proteomics Test Predicts Immunotherapy Benefit in NSCLC Independent of Genomic Alterations
2025 · Or Itzhaki, Michal Harel, et al. · The Journal of Liquid Biopsy
Plasma Proteomics as a Systemic Monitoring Approach in NSCLC Immunotherapy: Comparative Analysis with ctDNA
2025 · Yehuda Brody, Michal Harel, et al. · The Journal of Liquid Biopsy
PDF
63Plasma proteomic profiling reveals distinct mitochondrial signatures in chromophobe renal cell carcinoma
2025 · Clara Steiner, Hadi Mansour, et al. · The Oncologist
PDF
P2.06.93 Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis
2025 · D.R. Gandara, A.P. Dicker, et al. · Journal of Thoracic Oncology
1680P A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma
2025 · R.J. Sullivan, Y. Elon, et al. · Annals of Oncology
Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy.
2025 · Yehonatan Elon, Yehuda Brody, et al. · Journal of Clinical Oncology
PDF
A plasma proteomics-based model for predicting response to neoadjuvant chemotherapy in ovarian cancer.
2025 · Coren Lahav, Stav Sapoznik, et al. · Journal of Clinical Oncology
Circulating mitochondrial proteins as plasma biomarkers for chromophobe renal cell carcinoma.
2025 · Hadi Mansour, Clara Steiner, et al. · Journal of Clinical Oncology
PDF
Abstract 2058: Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors
2025 · Michal Harel, Nili Dahan, et al. · Cancer Research
CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning
2025 · Kimberly McGregor, Michal Harel, et al. · Journal of the National Comprehensive Cancer Network
Works count: 37
Citation count: 108
H-index: 5
I10-index: 3
Year
Topic
Type